All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What new developments are there in the treatment of relapsed or refractory MDS?

During the 63rd ASH Annual Meeting and Exposition, the MDS Hub was pleased to speak to Amer Zeidan, Yale School of Medicine, New Haven, US. We asked, What new developments are there in the treatment of relapsed or refractory myelodysplastic syndromes (MDS)?

What new developments are there in the treatment of relapsed or refractory MDS?

In this video, Zeidan discusses the treatment options for patients with MDS in the relapsed/refractory setting. In particular, he comments on the use of venetoclax, and hypomethylating agents such as azacitidine.

 

Share: